Case Report

A rare extensive clinical presentation of calciphylaxis due to primary hyperparathyroidism

Mohamad Safwan A.*, K. N. Vijayan, Akash S., Ashwini T., Muhammed Irfan K. P. C.

Department of General Surgery, Kerala Institute of Medical Sciences, Thiruvananthapuram, Kerala, India

Received: 08 September 2020
Accepted: 16 October 2020

*Correspondence:
Dr. Mohamad Safwan A.,
E-mail: mdsafwanmbbs@gmail.com

ABSTRACT

Calciphylaxis is a dreadful condition predominantly seen in chronic kidney disease patients on haemodialysis or following renal transplant. Calciphylaxis occurring in patients with normal kidney function is extremely rare. Here we present 53-year-old women presented with painful, extensive eschar-like skin lesions involving bilateral lower limb of 3 months of duration. She had hypercalcemia, high serum parathyroid hormone (PTH) levels and elevated alkaline phosphatase. Ultrasound neck and sestamibi scan demonstrated left inferior parathyroid adenoma. Lower limb radiographic studies showed subcutaneous calcification. Cutaneous biopsy confirmed calciphylaxis. Cinacalcet to control hypercalcemia, antibiotics and pain control medications were started. Left inferior parathyroidectomy and debridement of gangrenous lesions of lower limbs were performed. Histopathology was consistent with parathyroid adenoma. Lower limb wound started granulating with Vacuum-assisted closure (VAC) dressing and skin graft was planned. Unfortunately, she succumbed 11 weeks from surgery due to proximal myopathy, aspiration pneumonitis, sepsis and multiorgan failure.

Keywords: Calciphylaxis, Vascular calcification, Primary hyperparathyroidism, Parathyroidectomy

INTRODUCTION

Calciphylaxis is also known as calcific arteriolopathy and characterized by extremely painful and progressive cutaneous necrosis due to calcification and thrombosis of arterioles and capillaries in the dermis and subcutaneous fat. Incidence of uremic calciphylaxis in end-stage renal disease patients on dialysis is 1% with a prevalence of 4%- and 1-year mortality of 45-80%. Non-uremic calciphylaxis (NUC) is rather unusual, with higher (52%) mortality. Death is mostly due to sepsis, which occurs between 2 weeks to 1 year after diagnosis.

To the best of knowledge, an around 25 case of calciphylaxis due to primary hyperparathyroidism has been reported so far in world literature. This case had the most extensive presentation of calciphylaxis reported till date. Hence, report this case for its rarity as well as for highlighting its unusual presentation to contribute in part to the better understanding and awareness of this condition.

CASE REPORT

54 years old women presented with extensive painful blackish lesions involving bilateral lower limbs up to mid-thigh; sparing the feet, of 3 months duration. Her co-morbidities were type-II diabetic mellitus, hypertension and depressive disorder.

Clinical history revealed that she had been diagnosed and was being treated elsewhere conservatively as a case of bilateral lower limb cellulitis for the past 2 months. During her previous hospitalization, laboratory workup showed hypercalcemia (13.1 mg/dl), Computed tomography (CT) scan of lower limb revealed evidence
extensive calcific deposits in the subcutaneous plane of both lower limbs (Figure 1B).

As there was no relief of severe pain, inability to walk, worsening of skin patches and ulcers, she was referred to the institution.

In general examination she was well-oriented, obese and bed-ridden, vital signs were normal. She had pallor, pitting oedema over the dorsum of feet and weakness of limb muscles. Local examination showed multiple, circumferential, tender, necrotic leathery cutaneous plaques with irregular edges surrounded by violaceous brawny erythema over bilateral lower limb extending from mid-thigh up to ankle (Figure 1A). There was no local warmth and bilateral dorsalis pedis pulse were palpable.

Ultra-sonography (USG) of neck suggested left inferior parathyroid adenoma. Technetium (99m Tc) sestamibi localized adenoma involving left inferior parathyroid gland (Figure 2A). Thus, made a diagnosis of primary hyperparathyroidism due to left inferior parathyroid adenoma with suspected calciphylaxis. Had multi-disciplinary approach involving endocrinology, nephrology, infectious disease, cardiology, psychiatry and critical care medicine. She was started on broad spectrum intravenous antibiotics, intravenous normal saline, furosemide, oral cinacalcet 90 mg/day, daily colloid silver dressing and other supportive measures.

Under general anaesthesia, the neck was explored and left inferior parathyroid adenoma was excised (Figure 2B) along with intra-operative PTH assay followed by debridement of gangrenous patches of both lower limbs. Her pre-excision PTH level was 295 pg/ml which decreased to 95 pg/ml after 10 minutes post-excision, which satisfied Miami criteria. Her calcium declined to normal (9.1 mg/dl) post-operatively.

Dermo-cutaneous biopsy of lesion showed extensive fibrinoid necrosis of blood vessels with calcification and dermal vessel thrombosis which confirmed the diagnosis of calciphylaxis (Figure 3A, B, C). Histopathology examination of parathyroid gland was consistent with parathyroid adenoma weighing 2 gm. Her lower limb wounds improved and showed healthy granulation after treatment with vacuum-assisted closure dressing for 7 weeks (Figure 3D). She was planned for split skin graft.

Despite initial improvement with aggressive management, her general health deteriorated gradually. She developed difficulty in breathing and swallowing, hence was shifted to intensive care. Unfortunately, she had aspiration pneumonitis due to proximal muscle

---

Table 1: Laboratory results.

| Laboratory parameters               | Values | Inference |
|-------------------------------------|--------|-----------|
| Haemoglobin (g/dl)                  | 9      | Decreased |
| Total leukocyte count (cells/cu.mm) | 12600  | Increased |
| CRP (mg/dl)                         | 90     | Increased |
| Alkaline phosphatase (U/L)          | 140    | Increased |
| Urea (mg/dl)                        | 40     | Normal    |
| Creatinine (mg/dl)                  | 1.3    | Normal    |
| Calcium (mg/dl)                     | 13.1   | Increased |
| Phosphorus (mg/dl)                  | 3.8    | Normal    |
| Parathyroid hormone (pg/dl)         | 614.4  | Increased |
| 24-hour Urinary creatinine (mg/dl)  | 317    | Decreased |
| 24-hour Urinary calcium (mg/day)    | 218    | Normal    |
weakness which led to sepsis, multi-organ dysfunction syndrome and death after 80 days of hospitalization.

**Figure 3:** (A) Histopathology picture of gangrenous lesion showing dermo-cutaneous junction with intraluminal thrombosis of blood vessel (yellow arrow) and intravascular calcification (red arrow). (B) Histopathology picture of subcutaneous medium sized (red arrow) and small size vessel calcification (yellow arrow). (C) Histopathology picture showing features of acute panniculitis with neutrophil debris (red arrow) and small size vessel calcification (yellow arrow).

**DISCUSSION**

Calciphylaxis or vascular calcification-cutaneous necrosis syndrome was first described by Selye et al in 1962 as hypersensitivity reaction, based on their experiments on nephrectomised rats. However first case in humans with histopathological diagnosis of non-uremic calciphylaxis was reported in 1956.

Most common risk factor and co-morbidities associated with NUC are primary hyperparathyroidism, malignancy, alcoholic liver disease and connective tissue disorders. Others are obesity, female gender and rapid weight loss, diabetes, protein C and S deficiency, anti-phospholipid syndrome, vitamin D abnormalities and drugs like Warfarin and steroid.

The pathogenesis of NUC is not well understood. However, when serum calcium and phosphate levels are elevated, it leads to reduced solubility which results in calcium phosphate deposition in vessels, also known as metastatic calcification.

Aetiology like primary hyperparathyroidism, steroids use and liver disease is recognized in stimulating the expression of RANK ligand and reducing the expression of osteoprotegerin, thus activating NF-κB or breaking the inhibitory protein of NF-κB and resulting in osseous mineral loss and extra-osseous mineral deposition.

As there is no specific diagnostic test for NUC, the diagnosis mainly depends on the clinician's suspicion from history and physical examination. Initially, skin changes begin as violaceous mottling of the skin and induration in a livedo reticularis pattern. When tissue thrombosis and infarction occur, it produces excruciating painful, black leathery lesions which often gets superinfected. Lesions are common in areas where fat tissue is the most abundant. Distal extremities lesions are considered to have a better prognosis when compared to truncal lesions. Proximal muscle weakness is an infrequent manifestation of calciphylaxis which can occur even without cutaneous necrosis, due to ischemic myopathy.

A deep skin biopsy from the periphery of the lesion is necessary to confirm the diagnosis, especially in non-uremic patients. It shows calcium deposition within the arteriole-sized and small-sized vessel walls with endovascular fibrosis associated with fat necrosis, and neutrophil and macrophages infiltration.

Although, there is no approved treatment for calciphylaxis, it should be approached with multifaceted and inter-disciplinary strategy. Treatment must aim at prohibition or reversal of the vascular calcification by regulating calcium-phosphate homeostasis and prevention of lethal local and systemic septic complication along with medical therapy for optimizing associated co-morbid condition.

Parathyroidectomy surgical or chemical debridement of eschar-like cutaneous lesions and underlying inflamed adipose tissue to facilitate wound healing. Opiates for pain control, Cinacalcet helps in suppressing PTH which interacts with Ca-sensing receptor on parathyroid cells. Parathormone levels are high in non-uremic calciphylaxis and suppression of PTH could help in healing of eschars.

Intravenous or intralesional sodium thiosulphate increases the solubility of the calcium deposits along with its antioxidant and vasodilatory property has been reported in uremic calciphylaxis. Adequate hydration and nutritional support are very essential.

Non-calcium containing phosphate binders like sevelamer carbonate or lanthanum carbonate, bisphosphonates, hyperbaric oxygen therapy (HBOT) are used for the treatment of resistant calciphylaxis.

In this case, couldn’t use sodium thiosulphate, lanthanum carbonate and HBOT due to unavailability. However, VAC therapy helped in the rapid healing process.

**CONCLUSION**
Calciphylaxis is a terrible disease carrying high morbidity and mortality due to sepsis. A strong clinical suspicion must arise while managing patients with painful cutaneous ulcers with necrosis. Serum calcium screening and serum PTH should be done in such cases. Early identification and multi-faceted interdisciplinary treatment strategy with cinacalcet, parathyroidectomy, aggressive wound debridement followed by VAC therapy are required for a better outcome.

ACKNOWLEDGEMENTS

Author would like to thank Dr. Rachel Abraham and Dr. Rakesh Chandru for sharing their knowledge.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Dahl PR, Winkelmann RK, Connolly SM. The vascular calcification-cutaneous necrosis syndrome. J Am Acad Dermatol. 1995;33:53-8.
2. Nigwekar SU, Kroshinsky D, Nazarian RM, Gouverman J, Malhotra R, Jackson VA et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015;66:133-46.
3. Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 2008;3:1139-43.
4. Bishop J, Brown E, Podesta A, Troy C, Dong XE. Surgical management of calciphylaxis associated with primary hyperparathyroidism: a case report and review of the literature. Int J Endocrinol. 2010;2010:823210.
5. Mirza I, Chaubay D, Gunderia H, Shih W, El-Fanek H. An Unusual Presentation of Calciphylaxis Due to Primary Hyperparathyroidism. Arch Pathol Lab Med. 2001;125(10):1351-3.
6. Hemdani R, Rajput GR, Sridhar J, Chatterjee M, Rathod D. Calciphylaxis as cutaneous marker of hyperparathyroidism and successful outcome with parathyroidectomy followed by hyperbaric oxygen therapy. Indian J Dermatol Venereol Leprol. 2018;84(2):209-11.
7. Selye H, Gabbiani G, Strebel R. Sensitization to calciphylaxis by endogenous parathyroid hormone. Endocrinol. 1962;71:554-558.
8. Bogdonoff MD, Engel FL, White JE, Woods AH: Hyperparathyroidism. Am J Med. 1956;21:583-95.
9. Khaffif RA, Delima C, Silverberg A, Frankel R. Calciphylaxis and systemic calcinosis: collective review. Arch Intern Med. 1990;150:956-9.
10. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR et al. Catabolic effects of continuous human PTH (1e38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinol. 2001;142:4047-54.
11. Klaus W, Richard J, Arturo S. Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology, 7th ed. McGraw Hill. 2013:429.
12. Bleyer AJ, Choi M, Igwemezie B, de la Torre E, White WL. A case control study of proximal calciphylaxis. Am J Kidney Dis. 1998;32(3):376-83.
13. Salmhofer H, Franzen M, Hitzl W, Koller J, Kreymann B, Fend F et al. Multi-modal treatment of calciphylaxis with sodium-thiosulfate, cinacalcet and sevelamer including long-term data. Kidney Blood Press Res. 2013;37:346-359.
14. Arenas MD, Gil MT, Gutiérrez MD, Malek T, Moledous A, Salinas A et al. Management of calcific uremic arteriolopathy (calciphylaxis) with a combination of treatments, including hyperbaric oxygen therapy. Clin Nephrol. 2008;70:261-64.